share_log

四環醫藥：自願公告 - 四環集團聯營公司北京銳業開發的四款非PVC粉液雙室袋產品新增獲納入2023年國家醫保目錄

SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT - FOUR NON-PVC SOLID-LIQUID DOUBLE CHAMBER BAG PRODUCTS, DEVELOPED BY SIHUAN PHARMACEUTICAL''S ASSOCIATE COMPANY BEIJING RUIYE, ARE NEWLY INCLUDED IN NRDL 2023

香港交易所 ·  Jan 9 07:54
Summary by Moomoo AI
四環醫藥控股集團有限公司（「四環醫藥」）宣布，其聯營公司北京銳業制藥有限公司開發的四款非PVC粉液雙室袋產品成功獲納入2023年國家醫保目錄，其中三款產品在國內獨家。這些產品包括注射用頭孢地嗪鈉╱氯化鈉注射液等，均採用先進技術，能在20秒內完成配製，提高臨床應用的安全性和便捷性。北京銳業在非PVC粉液雙室袋產品的研發和市場佔有率方面領先，目前已有9個產品獲批上市。該產品類型在中國市場處於起步階段，但市場潛力巨大，預計將加速市場滲透。四環醫藥於2001年創立，2010年在香港上市，專注於創新藥物和醫美產品的研發與銷售。此次產品獲納入醫保目錄，將進一步提升患者使用意願，有助於推動公司業務發展和市場擴張。
四環醫藥控股集團有限公司（「四環醫藥」）宣布，其聯營公司北京銳業制藥有限公司開發的四款非PVC粉液雙室袋產品成功獲納入2023年國家醫保目錄，其中三款產品在國內獨家。這些產品包括注射用頭孢地嗪鈉╱氯化鈉注射液等，均採用先進技術，能在20秒內完成配製，提高臨床應用的安全性和便捷性。北京銳業在非PVC粉液雙室袋產品的研發和市場佔有率方面領先，目前已有9個產品獲批上市。該產品類型在中國市場處於起步階段，但市場潛力巨大，預計將加速市場滲透。四環醫藥於2001年創立，2010年在香港上市，專注於創新藥物和醫美產品的研發與銷售。此次產品獲納入醫保目錄，將進一步提升患者使用意願，有助於推動公司業務發展和市場擴張。
FOUR NON-PVC POWDER DOUBLE CHAMBER BAG PRODUCTS DEVELOPED BY ITS SUBSIDIARY BEIJING YUYI PHARMACEUTICAL CO., LTD., HAVE BEEN SUCCESSFULLY INCLUDED IN THE NATIONAL MEDICAL CATALOG 2023, THREE OF WHICH ARE EXCLUSIVE TO THE DOMESTIC MARKET. These products, including cephalodiazepine sodium/sodium chloride injections for injection, use advanced technology to be completed in 20 seconds, improving the safety and convenience of clinical applications. Beijing Jiuyue is a leader in the development and market share of non-PVC powder two-chamber bag products. 9 products have been approved for sale at present. The product type is in its infancy in the Chinese market, but the market potential is huge and is expected to accelerate market penetration. Founded in 2001 and listed in Hong Kong in 2010, Four Circle Pharmaceuticals focuses on the R&D and sale of innovative medicines and cosmetic products. The inclusion of this product in the healthcare catalog will further increase patient willingness to use it, helping to drive the company's business development and market expansion.
FOUR NON-PVC POWDER DOUBLE CHAMBER BAG PRODUCTS DEVELOPED BY ITS SUBSIDIARY BEIJING YUYI PHARMACEUTICAL CO., LTD., HAVE BEEN SUCCESSFULLY INCLUDED IN THE NATIONAL MEDICAL CATALOG 2023, THREE OF WHICH ARE EXCLUSIVE TO THE DOMESTIC MARKET. These products, including cephalodiazepine sodium/sodium chloride injections for injection, use advanced technology to be completed in 20 seconds, improving the safety and convenience of clinical applications. Beijing Jiuyue is a leader in the development and market share of non-PVC powder two-chamber bag products. 9 products have been approved for sale at present. The product type is in its infancy in the Chinese market, but the market potential is huge and is expected to accelerate market penetration. Founded in 2001 and listed in Hong Kong in 2010, Four Circle Pharmaceuticals focuses on the R&D and sale of innovative medicines and cosmetic products. The inclusion of this product in the healthcare catalog will further increase patient willingness to use it, helping to drive the company's business development and market expansion.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more